ArticleBritish journal of cancer2024

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.

Paola Roa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.